Details for Patent: 7,758,890

Title:	Treatment using dantrolene
Abstract:	Low volume safe for injection formulations of dantrolene yield significant advantages over the currently approved and marketed dantrolene for MH threatening anesthetic crisis. Once dantrolene can be made immediately available to patients triggered of MH, the anesthesiologist will be able to focus exclusively on the management of the patient's physiologic status in this complex and evolving crisis, not on the laborious and time consuming reconstitution process of the rescue agent. Additionally, a safe for injection low volume formulation of dantrolene can be made widely available to non-anesthesiologist practitioners who have occasion to use dantrolene intravenously in the treatment of other potentially life threatening conditions, including in the field. The low volume, safe for injection formulations of dantrolene, as well as other formulations of dantrolene, have significant advantages over currently used approaches to the prevention and treatment of pumphead, and other neurological, cognitive and motor dysfunction incident to iatrogenically or trauma induced situations of altered blood flow, including those incurred during surgical procedures involving CPB or related procedures, as well as those incurred during non-normothermic episodes caused iatrogenically or by disease.
Inventor(s):	Anderson; David (Ashland, VA), Cameransi, Jr.; Benjamin G. (Georgetown, SC), Conklin; Vincent M. (Richmond, VA)
Assignee:	Lyotropic Therapeutics, Inc. (Ashland, VA)
Filing Date:	Mar 01, 2004
Application Number:	10/788,413
Claims:	1. A safe for injection, low volume formulation of dantrolene sodium, for administration to mammals, comprising: dantrolene sodium at a concentration in the range of 30-80 mg/ml or in the range of 10-60 mg/ml; a water-soluble polysorbate; a compound selected from the group consisting of sorbitol and mannitol; and water as a liquid carrier, wherein said dantrolene sodium and water are present together as a colloidal dispersion of dantrolene sodium particles in the water, wherein the dantrolene sodium particles are less than about 2 microns in average diameter, and wherein the formulation is safe for intravenous administration. 2. The safe for injection, low volume formulation of claim 1, wherein the formulation consists essentially of: dantrolene sodium at a concentration in the range of 30-80 mg/ml or in the range of 10-60 mg/ml; a water-soluble polysorbate; a compound selected from the group consisting of sorbitol and mannitol: and water as a liquid carrier, wherein said dantrolene sodium and water are present together as a colloidal dispersion of dantrolene sodium particles in the water, wherein the dantrolene sodium particles are less than about 2 microns in average diameter, and wherein the formulation is safe for intravenous administration. 3. The safe for injection low volume formulation of claim 1, wherein the dantrolene sodium is the primary modulator of intracellular calcium present in the formulation. 4. The safe for injection, low volume formulation of claim 1, further comprising polyvinylpyrrolidone (PVP). 5. The safe for injection, low volume formulation of claim 4, consisting essentially of: dantrolene sodium at a concentration in the range of 30-80 mg/ml or in the range of 10-60 mg/ml; a water-soluble polysorbate; a compound selected from the group consisting of sorbitol and mannitol: polyvinylpyrrolidone (PVP); and water as a liquid carrier, wherein said dantrolene sodium and water are present together as a colloidal dispersion of dantrolene sodium particles in the water, wherein the dantrolene sodium particles are less than about 2 microns in average diameter, and wherein the formulation is safe for intravenous administration. 6. The safe for injection, low volume formulation of claim 1, wherein at least 95% of the dantrolene sodium particles in said liquid carrier are no more than 0.8 microns in diameter. 7. The safe for injection, low volume formulation of claim 1, wherein at least 95% of the dantrolene sodium particles in said liquid carrier are no more than 0.45 microns in diameter. 8. The safe for injection, low volume formulation of claim 1, wherein no particles of dantrolene sodium in said liquid carrier are more than 2 microns in diameter. 9. The safe for injection, low volume formulation of claim 1, wherein the compound is mannitol and the formulation comprises no more than 30 milligrams of mannitol per milligram of dantrolene. 10. The composition of claim 1, wherein said water soluble polysorbate has a solubility of 5 mg/ml or greater. 11. The composition of claim 1, further comprising a medicament different from said dantrolene sodium. 12. The composition of claim 1, comprising a quantity of liquid which permits administration of a therapeutic dose of dantrolene by injection of said composition to a patient. 13. The composition of claim 12 wherein said quantity ranges from 3-150 milliliters. 14. The composition of claim 12 wherein said quantity is 10 milliliters or less. 15. The composition of claim 12 wherein said quantity is 5 milliliters or less. 16. The safe for injection, low volume formulation of claim 1 comprising a dose of 250-300 mg dantrolene sodium and which can be safely administered to a human by a single bolus injection in less than one minute. 17. The safe for injection, low volume formulation of claim 16 comprising a dose of 250 mg of dantrolene sodium. 18. The safe for injection, low volume formulation of claim 1, wherein said dantrolene sodium is present at 50 mg/ml. 19. A safe for injection, low volume liquid formulation of dantrolene sodium for administration to mammals, comprising: dantrolene sodium at a concentration wherein 3 to 150 milliliters of the liquid formulation provides approximately 500 milligrams of the sodium dantrolene; a water-soluble polysorbate; a compound selected from the group consisting of sorbitol and mannitol; and water as a liquid carrier, wherein said dantrolene sodium and water are present together as a colloidal dispersion of dantrolene sodium particles in the water, wherein the dantrolene sodium particles are less than about 2 microns in average diameter, and wherein the formulation is safe for intravenous administration. 20. The safe for injection, low volume liquid formulation of dantrolene sodium of claim 19, consisting essentially of: dantrolene sodium at a concentration wherein 3 to 150 milliliters of the liquid formulation provides approximately 500 milligrams of the sodium dantrolene; a water-soluble polysorbate; a compound selected from the group consisting of sorbitol and mannitol; and water as a liquid carrier, wherein said dantrolene sodium and water are present together as a colloidal dispersion of dantrolene sodium particles in the water, wherein the dantrolene sodium particles are less than about 2 microns in average diameter, and wherein the formulation is safe for intravenous administration. 21. The safe for injection, low volume liquid formulation of dantrolene sodium of claim 19, consisting essentially of: dantrolene sodium at a concentration wherein 3 to 150 milliliters of the liquid formulation provides approximately 500 milligrams of the sodium dantrolene; a water-soluble polysorbate; a compound selected from the group consisting of sorbitol and mannitol; polyvinylpyrrolidone (PVP); and water as a liquid carrier, wherein said dantrolene sodium and water are present together as a colloidal dispersion of dantrolene sodium particles in the water, wherein the dantrolene sodium particles are less than about 2 microns in average diameter, and wherein the formulation is safe for intravenous administration.